Samsung Biologics, Vir partner on SARS-CoV-2 program

By The Science Advisory Board staff writers

April 10, 2020 -- Samsung Biologics announced it will manufacture Vir Biotechnology's SARS-CoV-2 monoclonal antibody (mAb) program for a potential COVID-19 treatment.

Vir's lead SARS-CoV-2 mAb development candidates, VIR-7831 and VIR-7832, have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralizing SARS-CoV-2 in live-virus cellular assays, according to the companies.

Within the next three to five months, Vir plans to proceed directly into a phase II clinical trial. Samsung Biologics is expected to begin manufacturing as early as October. Commercial batches may be manufactured starting in 2021, according to the companies.

The approximately $362 million deal between the companies builds on Vir's previously announced manufacturing agreement with WuXi Biologics and its letter of intent with Biogen.

Copyright © 2020

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?